Evidence map›Paper›PMID 34286631›Full record

ArticleDrug delivery2021

Tumor RNA-loaded nanoliposomes increases the anti-tumor immune response in colorectal cancer.

Dandong Dai, You Yin, Yuanbo Hu, Ying Lu, Hongbo Zou, GuangZhao Lu, Qianqian Wang, Jie Lian, Jie Gao, Xian Shen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug delivery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Biomaterials forGut microbes
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Dandong DaiDepartment of Gastrointestinal Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Zhejiang, China.ORCID 0000-0001-7705-8911
You YinInstitute of Translational Medicine, Shanghai University, Shanghai, China.
Yuanbo HuDepartment of Gastrointestinal Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Zhejiang, China.
Ying LuDepartment of Pharmaceutical Sciences, Naval Medical University, Shanghai, China.
Hongbo ZouDepartment of Gastrointestinal Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Zhejiang, China.
GuangZhao LuDepartment of Pharmaceutical Sciences, Naval Medical University, Shanghai, China.
Qianqian WangDepartment of Medical Oncology, Hangzhou First People's Hospital, Zhejiang, China.
Jie LianDepartment of Pathology, Shaoxing Shangyu People's Hospital, Zhejiang, China.
Jie GaoInstitute of Translational Medicine, Shanghai University, Shanghai, China.
Xian ShenDepartment of Gastrointestinal Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Zhejiang, China.
Wenzhou Medical University · CNShanghai University · CNHangzhou First People's Hospital · CNShaoxing People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTumor RNA vaccines can activate dendritic cells to generate systemic anti-tumor immune response. However, due to easily degraded of RNA, direct RNA vaccine is less effective. In this study, we optimized the method for preparing PEGylated liposom-polycationic DNA complex (LPD) nanoliposomes, increased encapsulate amount of total RNA derived from CT-26 colorectal cancer cells. Tumor RNA LPD nanoliposomes vaccines improved anti-tumor immune response ability of tumor RNA and can effectively promote anti-tumor therapeutic effect of oxaliplatin.

methodsTotal tumor-derived RNA was extracted from colorectal cancer cells (CT-26 cells), and loaded to our optimized the LPD complex, resulting in the LPD nanoliposomes. We evaluated the characteristics (size, zeta potential, and stability), cytotoxicity, transfection ability, and tumor-growth inhibitory efficacy of LPD nanoliposomes.

resultsThe improved LPD nanoliposomes exhibited a spherical shape, RNA loading efficiency of 9.07%, the average size of 120.37 ± 2.949 nm and zeta potential was 3.34 ± 0.056 mV. Also, the improved LPD nanoliposomes showed high stability at 4 °C, with a low toxicity and high cell transfection efficacy toward CT-26 colorectal cancer cells. Notably, the improved LPD nanoliposomes showed tumor growth inhibition by activating anti-tumor immune response in CT-26 colorectal cancer bearing mice, with mini side effects toward the normal organs of mice. Furthermore, the effect of the improved LPD nanoliposomes in combination with oxaliplatin can be better than that of oxaliplatin alone.

conclusionThe improved LPD nanoliposomes may serve as an effective vaccine to induce antitumor immunity, presenting a new treatment option for colorectal cancer.

Indexed as

AnimalsAntineoplastic AgentsCancer VaccinesCD8-Positive T-LymphocytesCell Line, TumorCell SurvivalChemistry, PharmaceuticalColorectal NeoplasmsDrug CarriersDrug StabilityDrug Therapy, CombinationLiposomesMaleMiceMice, Inbred BALB CNanoparticlesAntineoplastic AgentsCancer VaccinesDrug CarriersLiposomesOxaliplatinPolyethylene GlycolsRNAchemotherapyColorectal cancerLPDnanoliposomeRNA vaccinevaccine

Identifiers

PMID34286631
PMCPMC8297404
OpenAlexW3186596333

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.